SignalFDA/Bio
Arcutis outlines $535M-$545M 2026 net revenue guidance while preparing for February 23, 2027 infant AD PDUFA
Arcutis issued $535M–$545M 2026 revenue guidance ahead of its February 2027 infant AD PDUFA.
Context
What happened: Arcutis Biotherapeutics (ARQT) discussed Q3 2026 results on its earnings call, with management outlining 2026 net revenue guidance and preparation for an infant AD PDUFA date.
Key numbers: Q3 2026 net product revenues were $143.9 million. 2026 net revenue guidance is $535M to $545M. Infant AD PDUFA date is February 23, 2027.
Why it matters: Management said the company is reinvesting cash flow generated from ZORYVE back into the business, citing robust sales performance and demand-driven growth.
What changed
Arcutis Biotherapeutics (ARQT) discussed Q3 2026 results on its earnings call, with management outlining 2026 net revenue guidance and preparation for an infant AD PDUFA date.
Why it matters
Management said the company is reinvesting cash flow generated from ZORYVE back into the business, citing robust sales performance and demand-driven growth.